Financial news, mergers and acquisitions, partnerships, and alliances.
The group will define and quantify Stroma Liquid Biopsy biomarkers in Leiden University-collected sera to correlate them with Leiden's tumor-stroma ratio scoring methods.
MammaPrint classifies patients as either high risk or low risk of recurrence over a 10-year period while BluePrint classifies patients by breast cancer subtype.
FLX Bio will apply Personalis' ImmunoID Next platform as part of a Phase I/II clinical trial evaluating its FLX475 drug in cancer therapy.
The test will guide clinical decision making related to Inovio's DNA-based immunotherapy to treat cervical dysplasia caused by human papillomavirus.
During its earnings call this week, the liquid biopsy firm said it is planning a 10,000-patient trial to test its Lunar assay for colorectal cancer screening.